Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users (Q36952131)

17 August 2017

Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users (English)

1 reference

17 August 2017

1 reference

Andrew O Westfall

2

0 references

Jeffrey R Curtis

1

object named as

Jeffrey R Curtis

1 reference

17 August 2017

Hong Cheng

3

1 reference

17 August 2017

Kenneth Lyles

4

1 reference

17 August 2017

Kenneth G Saag

5

1 reference

17 August 2017

Elizabeth Delzell

6

1 reference

17 August 2017

1 September 2008

1 reference

Journal of Bone and Mineral Research

17 August 2017

1 reference

17 August 2017

23

1 reference

17 August 2017

9

1 reference

17 August 2017

1435-1441

1 reference

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Estimating medication persistency using administrative claims data.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Identification of fractures from computerized medicare files

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574615

Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18442318

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18442318

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1359/JBMR.080418

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

18442318

1 reference